Assorted News from the Last Week: The FDA granted accelerated approval to Eli Lilly And Co’s selpercatinib (Retevmo) for pediatric patients two years of age and
By CAC2 Member Matt Marks (Leukemia & Lymphoma Society) State borders shouldn’t be barriers to treatment for children with cancer or other complex illnesses. Yet
Assorted News from the Last Week: The FDA Pediatric ODAC met to “discuss perspectives on the impact of FDARA on the field of pediatric oncology,
The Energy and Commerce Committee advanced proposals earlier this month that will extend Americans’ access to telehealth services, strengthen and preserve Medicaid, and encourage innovation
Assorted News from the Last Week: St. Jude survivorship portal and its ability to facilitate breakthroughs in pediatric cancer survivorship research were published recently in Cancer
Assorted News from the Last Week: To understand how CNS tumors impact the AYA population, NCI-CONNECT (Comprehensive Oncology Network Evaluating Rare CNS Tumors), the Central
Assorted News from the Last Week: Brain cancer in children is notoriously hard to treat – a new mRNA cancer vaccine triggers an attack from
Assorted News from the Last Week: Congratulations to CAC2 Supporting Organization Day One Biopharmaceuticals. The FDA has granted accelerated approval to tovorafenib (Ojemda) for the
Assorted News from the Last Week: To achieve successful socioeconomic reintegration in the long term, it is crucial to implement a childhood cancer survivorship program
Assorted News from the Last Week: The UK’s National Institute for Health and Care Excellence (NICE) recommended Novartis’ autologous CAR T-cell therapy Kymriah (tisagenlecleucel) for
